MPXV e Mpox: Still a One Health Challenge?
Main Article Content
Abstract
The monkeypox virus (renamed MPXV), is a species of double-stranded DNA virus that causes Mpox disease in humans and other mammals. It is a zoonotic virus belonging to the Orthopoxvirus genus, making it closely related to the variola, cowpox, and vaccinia viruses. MPXV clade I has been affecting the Democratic Republic of Congo since nov- 2023. Spreading has been shown in other African countries (Burundi, Rwanda, Uganda and Kenya). On 15 August 2024, one case of MPXV clade Ib was reported in the EU. In countries reporting clade I cases, human-to-human transmission through close physical contact and through both sexual and non-sexual transmission has been documented. When the World Health Organization (WHO) declared on August 15, 2024 a public-health emergency over Mpox it was because a concerning form of the virus had spread to multiple African countries where it had never been seen before. Clade In is spreading largely through contact between humans, including through sexual contact. MPXVs have been listed by WHO as cause of pandemic potential. For Mpox/MPXV One Health approach may be critical to better understand biological and epidemiological evolution of the virus, since One Health is an integrated, unifying approach that aims to sustainably balance and optimize the health of humans, animals, plants and ecosystems. The approach recognizes the health of humans, domestic and wild animals, plants and the wider environment (including ecosystems) are closely linked and interdependent.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Shah S. - Le Scienze 2013; 537: 82-89
Scham S. – Corpi estranei – Ed. Le Scie, Mondadori 2024
Borgese L. - Monkeypox virus: morto un papa, se ne può fare un altro? - Ital. J. Prev. Diagn. Ther. Med. 2023; 6: 6-19
Reardon S. - Mpox is spreading — these are scientists’ key questions Nature 2024; 633: 16-17.
EMA/703119/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report Tecovirimat SIGA – 11 nov 2021.
EMA/369203/2013 Committee for Medicinal Products for Human Use (CHMP)-30 may 2013
Mazzotta V. et al. - Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study. eClinicalMedicine 2024;68: 102420 Published Online 12 January 2024 https://doi.org/10. 1016/j.eclinm.2023. 102420.
Kupferschmidt K. - Confused about the mpox outbreaks? Here’s what’s spreading, where, and why With three virus variants on the move in different populations, “it keeps getting more complicated by the day” Science-insider Aug, 24 – 2024 [o
Kibunku E.M. et al. - Clade I–Associated Mpox Cases Associated with Sexual Contact, the Democratic Republic of the Congo Emerging Infectious Diseases 2024; 30: 172-175
-Alakunle E et al. - A comprehensive review of monkeypox virus and mpox characteristics Front. Cell. Infect. Microbiol. 14:1360586. doi: 10.3389/fcimb.2024.1360586
- Cevik M. et al. – Editorial. The 2023 – 2024 multi-source mpox outbreaks of Clade I MPXV in sub-Saharan Africa: Alarm bell for Africa and the World. IJID Regions 12 (2024) 100397.
- Ogoina D. et al. Clinical review of human mpox. Clin Microbiol Infect 2023;29:1493-1501.
- Kinganda-Lusamaki E et al Clade I Mpox virus genomic diversity in the Democratic Republic of the Congo, 2018 - 2024: Predominance of Zoonotic Transmission. Preprint at medRxiv https:// doi.org/10.1101/2024.08.13.24311951 (2024).
Fonti di aggiornamento on line utilizzate per i dati riferiti nel testo:
Istituto Superiore di Sanità (Epicentro).
Ministero della Salute
World Health Organization
ECDC European Centre for Disease Prevention and Control
CDC